文献速递呼吸道感染呼吸危重症与机械通气

COVID-19急性肺炎无创呼吸支持:临床实践考量与研究优先方向

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research.
PubMed 文献 · Lancet Respir Med · 2021-11-09

在可升级至全力治疗的5120例中,37%进展为有创机械通气,78%存活至研究结束;以无创呼吸支持为治疗上限的1050例存活率为30%。两项随机对照试验提示无创通气在减少插管需求方面优于经鼻高流量氧疗,总体并发症发生率低。

要点

  • 无创呼吸支持在COVID-19急性呼吸衰竭中总体安全、并发症率低。
  • 两项随机对照试验提示无创通气较经鼻高流量氧疗减少插管需求。
  • 无创呼吸支持作为治疗上限时存活率仅30%,需重视治疗升级决策。

核心结论

  • 研究提示无创呼吸支持用于COVID-19患者安全、可改善资源利用,并可能带来更好的结局。

主要发现

  • 在可升级至全力治疗的5120例中,1880例(37%)进展为有创机械通气。
  • 4669例可评估患者中3658例(78%)存活至研究结束。
  • 以无创呼吸支持为治疗上限的1050例患者存活率为30%。
  • 两项随机对照试验提示无创通气在减少插管需求方面优于经鼻高流量氧疗。
  • 报告的并发症发生率低。

关键数值与推荐

  • 综述涉及的无创呼吸支持方式包括经鼻高流量氧疗、持续气道正压和双水平气道正压。
  • 两项随机对照试验支持无创通气在减少插管需求方面优于经鼻高流量氧疗。

临床怎么用

  • 临床可考虑将无创呼吸支持用于COVID-19相关急性呼吸衰竭,同时关注治疗升级时机。
  • 需认识到无创呼吸支持作为治疗上限时存活率较低,应结合病情评估是否升级为有创通气。

局限性

  • 证据主要来自观察性研究,随机对照试验仅2项。
  • 尚需前瞻性随机研究明确干预时机、无创呼吸支持方式的单独或联合使用,以及氧合指数、无创呼吸支持试验反应和炎症标志物等预测工具的验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-invasive respiratory support (NIRS) has increasingly been used in the management of COVID-19-associated acute respiratory failure, but questions remain about the utility, safety, and outcome benefit of NIRS strategies. We identified two randomised controlled trials and 83 observational studies, compromising 13 931 patients, that examined the effects of NIRS modalities-high-flow nasal oxygen, continuous positive airway pressure, and bilevel positive airway pressure-on patients with COVID-19. Of 5120 patients who were candidates for full treatment escalation, 1880 (37%) progressed to invasive mechanical ventilation and 3658 of 4669 (78%) survived to study end. Survival was 30% among the 1050 patients for whom NIRS was the stated ceiling of treatment. The two randomised controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation. Reported complication rates were low. Overall, the studies indicate that NIRS in patients with COVID-19 is safe, improves resource utilisation, and might be associated with better outcomes. To guide clinical decision making, prospective, randomised studies are needed to address timing of intervention, optimal use of NIRS modalities-alone or in combination-and validation of tools such as oxygenation indices, response to a trial of NIRS, and inflammatory markers as predictors of treatment success.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Weerakkody S, Arina P, Glenister J, et al. Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research. Lancet Respir Med. 2021. PMID: 34767767. doi:10.1016/S2213-2600(21)00414-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。